Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Eprotirome is a liver selective thyroid hormone that can reduce several independent risk
factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic
tissue.
The purpose of this Phase III study is to assess the long-term efficacy and safety of
Eprotirome in Patients with heterozygous Familial Hypercholesterolaemia who are on optimal
standard of care.